SCHEMBL6524477

SCHEMBL6524477

S=C(NCCc1ccccc1)NCCc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 1.00
NPC1 O15118 5/20 1.00
SMN1; SMN2 Q16637 3/20 1.00
LMNA P02545 5/20 0.78
GAA P10253 2/20 0.78
TAAR1 Q96RJ0 2/20 0.78
MAOA P21397 1/20 0.75
MAOB P27338 1/20 0.75
MEN1 O00255 4/20 0.73
KMT2A Q03164 4/20 0.73
MAPT P10636 3/20 0.73
ALDH1A1 P00352 3/20 0.73
MAPK1 P28482 3/20 0.73
ALOX12 P18054 2/20 0.73
HTT P42858 1/20 0.73
TDP1 Q9NUW8 1/20 0.73
CA12 O43570 1/20 0.68
CA1 P00915 1/20 0.68
CA2 P00918 1/20 0.68
CA9 Q16790 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL158616 0.90 RAB9A (0.81) RAB9ANPC1SMN1; SMN2LMNAGAA
SCHEMBL6516283 0.89 KMT2A (0.88) RAB9ANPC1SMN1; SMN2LMNAGAA
SCHEMBL1968541 0.88 LMNA (1.00) RAB9ANPC1SMN1; SMN2LMNAGAA
SCHEMBL11632322 0.88 RAB9A (0.78) RAB9ANPC1SMN1; SMN2LMNAGAA
SCHEMBL159163 0.86 NPC1 (0.76) RAB9ANPC1SMN1; SMN2LMNAGAA
SCHEMBL1520437 0.86 RAB9A (1.00) RAB9ANPC1SMN1; SMN2LMNAGAA
SCHEMBL19376067 0.84 GAA (0.71) RAB9ANPC1SMN1; SMN2LMNAGAA
SCHEMBL15398364 0.84 MEN1 (0.75) RAB9ANPC1SMN1; SMN2LMNAGAA
SCHEMBL20027158 0.83 RAB9A (1.00) RAB9ANPC1SMN1; SMN2LMNAGAA
SCHEMBL19371412 0.83 RAB9A (0.70) RAB9ANPC1SMN1; SMN2LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050096473-A1 Thiourea and urea liquid-phase combinatorial libraries: synthesis and apoptosis induction PARKER HUGHES INSTITUTE (US) 2005-05-05 US disclosed
US-6794541-B2 REACTING 1,1'-THIOCARBONYLDIIMIDAZOLE WITH AN AMINE SUCH AS BENZYLAMINE TO FORM VARIOUS THIOUREA PRODUCTS; KILLING CANCER CELLS; TREATING LEUKEMIA PARKER HUGHES INSTITUTE 2004-09-21 US disclosed
US-20020103380-A1 Thiourea and urea liquid-phase combinatorial libraries: synthesis and apoptosis induction PARKER HUGHES INSTITUTE 2002-08-01 US disclosed
WO-2000056681-A9 THIOUREA AND UREA LIQUID-PHASE COMBINATORIAL LIBRARIES: SYNTHESIS AND APOPTOSIS INDUCTION PARKER HUGHES INST (US) 2001-11-22 WO disclosed
US-4775677-A ANTIALLERGNES, ANTIINFLAMMATORY AGENTS, CARDIOVASCULAR DISORDERS WARNER-LAMBERT COMPANY (US) 1988-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096473-A1 Thiourea and urea liquid-phase combinatorial libraries: synthesis and apoptosis induction CASP3, MCL1, BAD RAB9A 4065/4885NPC1 3968/4885SMN1; SMN2 3766/4885
US-20020103380-A1 Thiourea and urea liquid-phase combinatorial libraries: synthesis and apoptosis induction CASP3, MCL1, BAD RAB9A 4065/4885NPC1 3968/4885SMN1; SMN2 3766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.